cost effectiveness【会计】 - PMC

Result Filters

You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 660197

<< First< Prev

Page of 33010

Next >Last >>

Select item 64974461.

Cost-Effectiveness Analysis in Cardiac Surgery: a Review of Its Concepts and Methodologies

Bart S. Ferket, Jonathan M. Oxman, Alexander Iribarne, Annetine C. Gelijns, Alan J. Moskowitz

J Thorac Cardiovasc Surg. Author manuscript; available in PMC 2019 May 2.

Published in final edited form as: J Thorac Cardiovasc Surg. 2018 Apr; 155(4): 1671–1681.e11. Published online 2017 Nov 15. doi: 10.1016/j.jtcvs.2017.11.018

PMCID:: PMC6497446

Article PDF–684K

Select item 64262022.

Cost-effectiveness of community-based gendered advisory services to farmers: Analysis in Mozambique and Tanzania

Tewodaj Mogues, Valerie Mueller, Florence Kondylis

PLoS One. 2019; 14(3): e0211448. Published online 2019 Mar 20. doi: 10.1371/journal.pone.0211448

PMCID:: PMC6426202

Article PDF–785K

Select item 60903463.

Snakebite: An Exploratory Cost-Effectiveness Analysis of Adjunct Treatment Strategies

Benjamin J. Herzel, Stephen P. Samuel, Tommaso C. Bulfone, C. Soundara Raj, Matthew Lewin, James G. Kahn

Am J Trop Med Hyg. 2018 Aug; 99(2): 404–412. Published online 2018 Jun 4. doi: 10.4269/ajtmh.17-0922

PMCID:: PMC6090346

Article PDF–721K

Select item 98579514.

Cost-Effectiveness Analysis of Hp and New Gastric Cancer Screening Scoring System for Screening and Prevention of Gastric Cancer

Peiyu Zheng, Jinchun Liu

Curr Oncol. 2023 Jan; 30(1): 1132–1145. Published online 2023 Jan 13. doi: 10.3390/curroncol30010086

PMCID:: PMC9857951

Article PDF–3.0M

Select item 104688915.

Cost-effectiveness analysis of Smart Triage, a data-driven pediatric sepsis triage platform in Eastern Uganda

Edmond C. K. Li, Abner Tagoola, Clare Komugisha, Annette Mary Nabweteme, Yashodani Pillay, J. Mark Ansermino, Asif R. Khowaja

BMC Health Serv Res. 2023; 23: 932. Published online 2023 Aug 31. doi: 10.1186/s12913-023-09977-5

PMCID:: PMC10468891

Article PDF–1.3M

Select item 87343656.

Evidence-based cardiovascular magnetic resonance cost-effectiveness calculator for the detection of significant coronary artery disease

Ankur Pandya, Yuan-Jui Yu, Yin Ge, Eike Nagel, Raymond Y. Kwong, Rafidah Abu Bakar, John D. Grizzard, Alexander E. Merkler, Ntobeko Ntusi, Steffen E. Petersen, Nina Rashedi, Juerg Schwitter, Joseph B. Selvanayagam, James A. White, James Carr, Subha V. Raman, Orlando P. Simonetti, Chiara Bucciarelli-Ducci, Lilia M. Sierra-Galan, Victor A. Ferrari, Mona Bhatia, Sebastian Kelle

J Cardiovasc Magn Reson. 2022; 24: 1. Published online 2022 Jan 6. doi: 10.1186/s12968-021-00833-1

Correction in:: J Cardiovasc Magn Reson. 2022; 24: 17.

PMCID:: PMC8734365

Article PDF–1.3M

Select item 109872897.

A Tutorial on Net Benefit Regression for Real-World Cost-Effectiveness Analysis Using Censored Data from Randomized or Observational Studies

Shuai Chen, Heejung Bang, Jeffrey S. Hoch

Med Decis Making. 2024 Apr; 44(3): 239–251. Published online 2024 Feb 12. doi: 10.1177/0272989X241230071

PMCID:: PMC10987289

Article PDF–457K

Select item 101366358.

Real-World Cost-Effectiveness Analysis: How Much Uncertainty Is in the Results?

Heather K. Barr, Andrea M. Guggenbickler, Jeffrey S. Hoch, Carolyn S. Dewa

Curr Oncol. 2023 Apr; 30(4): 4078–4093. Published online 2023 Apr 7. doi: 10.3390/curroncol30040310

PMCID:: PMC10136635

Article PDF–1.5M

Select item 88663379.

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

Timothy Spelman, William L. Herring, Yuanhui Zhang, Michael Tempest, Isobel Pearson, Ulrich Freudensprung, Carlos Acosta, Thibaut Dort, Robert Hyde, Eva Havrdova, Dana Horakova, Maria Trojano, Giovanna De Luca, Alessandra Lugaresi, Guillermo Izquierdo, Pierre Grammond, Pierre Duquette, Raed Alroughani, Eugenio Pucci, Franco Granella, Jeannette Lechner-Scott, Patrizia Sola, Diana Ferraro, Francois Grand’Maison, Murat Terzi, Csilla Rozsa, Cavit Boz, Raymond Hupperts, Vincent Van Pesch, Celia Oreja-Guevara, Anneke van der Walt, Vilija G. Jokubaitis, Tomas Kalincik, Helmut Butzkueven, The MSBase Investigators

Pharmacoeconomics. 2022; 40(3): 323–339. Published online 2021 Dec 18. doi: 10.1007/s40273-021-01106-6

PMCID:: PMC8866337

Article PDF–1.6M

Select item 786755710.

Dealing with Bad Risk in Cost-Effectiveness Analysis: The Cost-Effectiveness Risk-Aversion Curve

Pedram Sendi

Pharmacoeconomics. 2021; 39(2): 161–169. Published online 2020 Oct 31. doi: 10.1007/s40273-020-00969-5

PMCID:: PMC7867557

Article PDF–2.5M

Select item 1056332311.

The use of cost-effectiveness analysis for health benefit package design – should countries follow a sectoral, incremental or hybrid approach?

Rob Baltussen, Gavin Surgey, Anna Vassall, Ole F. Norheim, Kalipso Chalkidou, Sameen Siddiqi, Mojtaba Nouhi, Sitaporn Youngkong, Maarten Jansen, Leon Bijlmakers, Wija Oortwijn

Cost Eff Resour Alloc. 2023; 21: 75. Published online 2023 Oct 9. doi: 10.1186/s12962-023-00484-2

PMCID:: PMC10563323

Article PDF–945K

Select item 919703612.

Cost-effectiveness analysis of bundled innovative devices versus standard approach in the prevention of unscheduled peripheral venous catheters removal due to complications in France

Franck Maunoury, Bertrand Drugeon, Matthieu Boisson, Nicolas Marjanovic, Raphael Couvreur, Olivier Mimoz, Jeremy Guenezan, on behalf of the CLEAN-3 Study

PLoS One. 2022; 17(6): e0269750. Published online 2022 Jun 14. doi: 10.1371/journal.pone.0269750

PMCID:: PMC9197036

Article PDF–873K

Select item 1003253413.

What, how and who: Cost-effectiveness analyses of COVID-19 vaccination to inform key policies in Nigeria

Francis J. Ruiz, Sergio Torres-Rueda, Carl A. B. Pearson, Eleanor Bergren, Chinyere Okeke, Simon R. Procter, Andres Madriz-Montero, Mark Jit, Anna Vassall, Benjamin S. C. Uzochukwu

PLOS Glob Public Health. 2023; 3(3): e0001693. Published online 2023 Mar 22. doi: 10.1371/journal.pgph.0001693

PMCID:: PMC10032534

Article PDF–1.9M

Select item 1045329814.

Carrier Screening Programs for Cystic Fibrosis, Fragile X Syndrome, Hemoglobinopathies and Thalassemia, and Spinal Muscular Atrophy: A Health Technology Assessment

Ontario Health (Quality)

Ont Health Technol Assess Ser. 2023; 23(4): 1–398. Published online 2023 Aug 10.

PMCID:: PMC10453298

Article PDF–5.2M

Select item 856230115.

Big Data and Real-World Data based Cost-Effectiveness Studies and Decision-making Models: A Systematic Review and Analysis

Z. Kevin Lu, Xiaomo Xiong, Taiying Lee, Jun Wu, Jing Yuan, Bin Jiang

Front Pharmacol. 2021; 12: 700012. Published online 2021 Oct 19. doi: 10.3389/fphar.2021.700012

Correction in:: Front Pharmacol. 2021; 12: 833827.

PMCID:: PMC8562301

Article PDF–2.0M

Select item 734473616.

Real-World Setting Cost-Effectiveness Analysis Comparing Three Therapeutic Schemes of One-Year Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer from the Cyprus NHS Payer Perspective

Savvas S. Ioannou, Yiola Marcou, Eleni Kakouri, Michael A. Talias

Int J Environ Res Public Health. 2020 Jun; 17(12): 4339. Published online 2020 Jun 17. doi: 10.3390/ijerph17124339

PMCID:: PMC7344736

Article PDF–748K

Select item 876014617.

Optimal control and comprehensive cost-effectiveness analysis for COVID-19

Joshua Kiddy K. Asamoah, Eric Okyere, Afeez Abidemi, Stephen E. Moore, Gui-Quan Sun, Zhen Jin, Edward Acheampong, Joseph Frank Gordon

Results Phys. 2022 Feb; 33: 105177. Published online 2022 Jan 15. doi: 10.1016/j.rinp.2022.105177

PMCID:: PMC8760146

Article PDF–1.4M

Select item 530880318.

Taxes and Subsidies for Improving Diet and Population Health in Australia: A Cost-Effectiveness Modelling Study

Linda J. Cobiac, King Tam, Lennert Veerman, Tony Blakely

PLoS Med. 2017 Feb; 14(2): e1002232. Published online 2017 Feb 14. doi: 10.1371/journal.pmed.1002232

PMCID:: PMC5308803

Article PDF–1.3M

Select item 884240219.

Systematic review of cost-effectiveness analysis of behavior change communication apps: Assessment of key methods

Cynthia Afedi Hazel, Sheana Bull, Elizabeth Greenwell, Maya Bunik, Jini Puma, Marcelo Perraillon

Digit Health. 2021 Jan-Dec; 7: 20552076211000559. Published online 2021 Mar 26. doi: 10.1177/20552076211000559

PMCID:: PMC8842402

Article PDF–527K

Select item 960492220.

The Merits, Limitations, and Future Directions of Cost-Effectiveness Analysis in Cardiac MRI with a Focus on Coronary Artery Disease: A Literature Review

Taha A. Siddiqui, Kiran S. Chamarti, Leila C. Tou, Gregory A. Demirjian, Sarah Noorani, Sydney Zink, Muhammad Umair

J Cardiovasc Dev Dis. 2022 Oct; 9(10): 357. Published online 2022 Oct 17. doi: 10.3390/jcdd9100357

PMCID:: PMC9604922

Article PDF–803K

<< First< Prev

Page of 33010

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

PMC Images search for cost effectiveness【会计】

Fig 4Cost-effectiveness plane including cost-effectiveness frontier: All trials.

Each point denotes a comparator and the line denotes the cost-effectiveness frontier. This links all non-dominated comparators and therefore shows the set of comparators that could be cost-effective depending upon the cost-effectiveness threshold. The slope of the line connecting a comparator on the cost-effectiveness frontier to a lower cost comparator is equal to the incremental cost-effectiveness ratio (ICER). NMES = neuromuscular electrical stimulation; TENS = transcutaneous electrical nerve stimulation.

Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee

PLoS One. 2017;12(3):e0172749.
Fig 5Cost-effectiveness plane including cost-effectiveness frontier: Trials at low risk of selection bias.

Each point denotes a comparator and the line denotes the cost-effectiveness frontier. This links all non-dominated comparators and therefore shows the set of comparators that could be cost-effective depending upon the cost-effectiveness threshold. The slope of the line connecting a comparator on the cost-effectiveness frontier to a lower cost comparator is equal to the incremental cost-effectiveness ratio (ICER). TENS = transcutaneous electrical nerve stimulation.

Cost-effectiveness of adjunct non-pharmacological interventions for osteoarthritis of the knee

PLoS One. 2017;12(3):e0172749.
Fig. 1Cost effectiveness planes and cost-effectiveness acceptability curves for vaccination scenarios in South Africa.

Top row (panels 1–3) shows cost-effectiveness planes (scatter plot) and cost-effectiveness acceptability curves (line graph) for three scenarios with pre- and post-infection vaccine efficacy. Bottom row (panels 4–6) shows cost-effectiveness planes and cost-effectiveness acceptability curves for three scenarios of post-infection-only vaccine efficacy. P&PI denotes vaccine with pre- and post-infection. PI denotes vaccine with post-infection efficacy only. DALY disability-adjusted life year, USD United States Dollars, WTP willingness to pay.

Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India

Nat Commun. 2022;13:602.
Fig. 2Cost effectiveness planes showing incremental cost-effectiveness ratios for vaccine introduction scenarios in India.

Top row (panels 1–3) shows cost-effectiveness planes (scatter plot) and cost-effectiveness acceptability curves (line graph) for three scenarios with pre- and post-infection vaccine efficacy. Bottom row (panels 4–6) shows cost-effectiveness planes and cost-effectiveness acceptability curves for three scenarios of post-infection-only vaccine efficacy. P&PI denotes vaccine with pre- and post-infection. PI denotes vaccine with post-infection efficacy only. DALY disability-adjusted life year, USD United States Dollars, WTP willingness to pay.

Cost-effectiveness of routine adolescent vaccination with an M72/AS01E-like tuberculosis vaccine in South Africa and India

Nat Commun. 2022;13:602.